Clinical Trials
5
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)Phase I Study of GST-HG151 Tablets in Healthy Volunteers
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT05345964
- Locations
- 🇨🇳
Mengchao Hepatpbiliary Hospital of Fujian Medical University, Fujian, Fuzhou, China
Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets
Phase 1
Completed
- Conditions
- Hepatitis B
- Interventions
- Drug: GST-HG141 tabletsDrug: Matching Placebos for GST-HG141 tablets
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT04868981
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets
Phase 1
- Conditions
- Hepatitis B
- Interventions
- Drug: GST-HG131 tabletsDrug: Placebo
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
- Target Recruit Count
- 124
- Registration Number
- NCT04499443
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets
Phase 1
- Conditions
- Hepatitis B
- Interventions
- Drug: GST-HG141 tabletsDrug: Placebo
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
- Target Recruit Count
- 104
- Registration Number
- NCT04386915
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT04228406
- Locations
- 🇨🇳
Shanghai Oriental Hospital, Shanghai, Shanghai, China
News
No news found